Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Eur Heart J. 2013 Feb;34(7):540-548a. doi: 10.1093/eurheartj/ehs197. Epub 2012 Jul 6.
The mechanisms mediating kidney injury and repair in humans with atherosclerotic renal artery stenosis (ARAS) remain poorly understood. We hypothesized that the stenotic kidney releases inflammatory mediators and recruits progenitor cells to promote regeneration.
Essential hypertensive (EH) and ARAS patients (n=24 each) were studied during controlled sodium intake and antihypertensive treatment. Inferior vena cava (IVC) and renal vein (RV) levels of CD34+/KDR+ progenitor cells, cell adhesion molecules, inflammatory biomarkers, progenitor cell homing signals, and pro-angiogenic factors were measured in EH and ARAS, and their gradient and net release compared with systemic levels in matched normotensive controls (n= 24). Blood pressure in ARAS was similar to EH, but the glomerular filtration rate was lower. Renal vein levels of soluble E-Selectin, vascular cell adhesion molecule-1, and several inflammatory markers were higher in the stenotic kidney RV vs. normal and EH RV (P < 0.05), and their net release increased. Similarly, stem-cell homing factor levels increased in the stenotic kidney RV. Systemic CD34+/KDR+ progenitor cell levels were lower in both EH and ARAS and correlated with cytokine levels. Moreover, CD34+/KDR+ progenitor cells developed a negative gradient across the ARAS kidney, suggesting progenitor cell retention. The non-stenotic kidney also showed signs of inflammatory processes, which were more subtle than in the stenotic kidney.
Renal vein blood from post-stenotic human kidneys has multiple markers reflecting active inflammation that portends kidney injury and reduced function. CD34+/KDR+ progenitor cells sequestered within these kidneys may participate in reparative processes. These inflammation-related pathways and limited circulating progenitor cells may serve as novel therapeutic targets to repair the stenotic kidney.
导致人类动脉粥样硬化性肾动脉狭窄(ARAS)患者肾损伤和修复的机制仍知之甚少。我们假设狭窄肾脏会释放炎症介质并募集祖细胞以促进再生。
在控制钠摄入和降压治疗的情况下,研究了 24 例原发性高血压(EH)和 ARAS 患者。在 EH 和 ARAS 中测量了下腔静脉(IVC)和肾静脉(RV)中的 CD34+/KDR+祖细胞、细胞黏附分子、炎症生物标志物、祖细胞归巢信号和促血管生成因子的水平,并与匹配的正常血压对照组(n=24)的系统水平进行了比较。ARAS 的血压与 EH 相似,但肾小球滤过率较低。与正常和 EH 的 RV 相比,狭窄肾 RV 中的可溶性 E-选择素、血管细胞黏附分子-1 和几种炎症标志物的水平更高(P<0.05),且其净释放增加。同样,RV 中的祖细胞归巢因子水平也增加。EH 和 ARAS 患者的全身 CD34+/KDR+祖细胞水平均较低,且与细胞因子水平相关。此外,CD34+/KDR+祖细胞在 ARAS 肾脏中呈负梯度分布,提示祖细胞滞留。非狭窄肾脏也显示出炎症过程的迹象,但比狭窄肾脏更为微妙。
来自 ARAS 患者狭窄后肾脏的肾静脉血液有多种标志物,反映了活跃的炎症,预示着肾脏损伤和功能下降。滞留在这些肾脏中的 CD34+/KDR+祖细胞可能参与修复过程。这些与炎症相关的途径和有限的循环祖细胞可能成为修复狭窄肾脏的新治疗靶点。